Castle Biosciences (CSTL) Corporate presentation summary

Strategic highlights

• Focus on innovative diagnostic tests addressing high unmet clinical needs in dermatology, gastroenterology, and ophthalmology.

• Mission centers on improving health and transforming disease management by prioritizing patients, clinicians, employees, and investors.

• Strategy emphasizes building robust clinical evidence, targeting significant market opportunities, and driving test adoption among clinicians and payers.

• Disciplined capital allocation supports commercial optimization, focused R&D, and strategic opportunities within core therapeutic areas.

• Positioned for continued value creation through test volume growth, strong margins, and a solid balance sheet.

Financial performance

• Second quarter 2026 revenue reached $103.5M, with a 32% year-over-year increase in core test report volumes.

• Adjusted gross margin was 76.3%, and adjusted EBITDA was $12.4M for the quarter.

• Cash, cash equivalents, and marketable investment securities totaled $266.8M as of June 30, 2026.

• Raised 2026 total revenue guidance to $365–375M, up from previous guidance.

Clinical portfolio and market opportunity

• Dermatology franchise includes DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, and AdvanceAD-Tx, targeting a combined U.S. TAM of over $34B.

• Gastroenterology portfolio features TissueCypher for Barrett's Esophagus, with a $1B U.S. TAM, and pipeline tests for GI diseases.

• Ophthalmology includes DecisionDx-UM, the standard of care for metastatic risk in uveal melanoma, used in ~80% of new cases.